Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Clear Cell Ovarian or Endometrial Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT05001282
What this trial is testing

Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Who this might be right for
Ovarian CancerOvarian NeoplasmsOvarian Carcinoma+22 more
Elucida Oncology 79
Early research (Phase 1)Study completedNCT02020707
What this trial is testing

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Who this might be right for
Cervical AdenocarcinomaCervical AdenosarcomaCervical Adenosquamous Carcinoma+45 more
Mayo Clinic 43
Not applicableWithdrawnNCT00499291
What this trial is testing

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors

Who this might be right for
Cancer
Eastern Cooperative Oncology Group
Testing effectiveness (Phase 2)Study completedNCT01935934
What this trial is testing

Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Who this might be right for
Endometrial Adenosquamous CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Mixed Cell Adenocarcinoma+7 more
National Cancer Institute (NCI) 102
Testing effectiveness (Phase 2)Active Not RecruitingNCT03348631
What this trial is testing

Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer

Who this might be right for
Recurrent Endometrial Endometrioid AdenocarcinomaRecurrent Malignant Uterine Corpus NeoplasmRecurrent Ovarian Carcinoma+2 more
National Cancer Institute (NCI) 62